Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
Psyched: 9 US Reform Bills, Ayahuasca ‘A Release’ For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization
Throughout the 2023 session, numerous discussions have been held and various measures have been considered around the legalization of psychedelics.
Let’s go over the latest proposed regulations.
Adastra Clarifies Health Canada Approval To Handle Cocaine
Adastra Labs Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) provided clarification regarding its receipt of Health Canada approval for the amendment to include cocaine under its controlled substances license.
Canadian Weed Company’s Plan To Produce Cocaine Shocks Local Leader, Opposition Questions Drug Experiment
A Langley, British Columbia, cannabis company got the green light from Health Canada to produce and sell cocaine earlier this month, but the province's Premier says he was unaware of the mo
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal’s Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health
The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.
Adastra Q3 Revenue Grows 110% YoY To $2.83M
Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX)(FRA:D2EP), released its financial results for the three and nine months ended September 30, 2022.
Q3 2022 Financial Highlights
Adastra Steps Into Magic Mushrooms! Gets Dealer’s License For Psilocybin And Psilocin
Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) has received its Controlled Drug and Substances Dealer's License on August 24, 2022. This license allows Adastra to process psilocybin and psilocin, the active compounds derived from psychedelic mushrooms.
Cannabis Movers & Shakers: OnPoint Laboratories, Neptune Wellness, Adastra Holdings & Cannaverse Technologies
OnPoint Laboratories Names Samuel Richard CEO & Equity Partner
OnPoint Laboratories has appointed Samuel Richard to serve as CEO and equity partner.
Richard succeeds Jeff Cardot, founder and current CEO, as part of a planned transition.
Adastra Holdings Appoints Smoke Wallin As New Director
Adastra Holdings Ltd. (OTCPK: XTXXF) (FRA: D2EP) appointed Smoke Wallin to the company's board of directors.
Wallin Responds
Adastra Holdings Reports Record Revenue In 2021, Here Are The Details
Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) has filed its consolidated financial statements and related management discussion and analysis for the year ended December 31, 2021.